Finding My Way-Advanced: can a web-based psychosocial intervention improve the mental quality of life for women with metastatic breast cancer vs attention-control? Study protocol of a randomised controlled trial.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
24 Dec 2022
Historique:
received: 06 10 2022
accepted: 05 12 2022
entrez: 24 12 2022
pubmed: 25 12 2022
medline: 28 12 2022
Statut: epublish

Résumé

Women living with metastatic breast cancer (MBC) are at risk of significantly impaired quality of life (QOL), symptom burden, distress and fear of progression, and unmet needs, yet they face barriers to accessing evidence-based psychosocial treatments. Our group therefore developed Finding My Way-Advanced (FMW-A), a web-based self-guided psychosocial program for women with MBC. This study aims to assess its efficacy in improving mental and other QOL domains, distress, fear of progression, unmet needs, and health service utilisation. The multi-site randomised controlled trial (RCT) will enrol 370 Australian participants. Eligible participants are adult (18 years +) women diagnosed with MBC, with a life expectancy of 6 months or more, with sufficient English-language literacy to provide informed consent. Participants will be identified, screened and referred from one of 10 Australian sites, or via self-referral in response to advertisements. Participants complete four online questionnaires: prior to accessing their program ('baseline'), 6 weeks later ('post-intervention'), then 3 months and 6 months post-intervention. Consenting participants will be randomised to either FMW-A (intervention), or Breast Cancer Network Australia's (BCNA) online/app resource My Journey (minimal intervention attention-control). This is a single-blind study, with randomisation computer-generated and stratified by site. FMW-A is a 6-module program addressing some of the most common issues experienced by women with MBC, with BCNA control resources integrated within the 'resources' section. All modules are immediately accessible, with an additional booster module released 10 weeks later. The primary outcome is mental QOL; statistical criteria for superiority is defined as a 4-point difference between groups at post-treatment. Secondary outcomes include other QOL domains, distress, fear of progression, health service use, intervention adherence, and user satisfaction. This will be the first adequately powered RCT of a self-directed online intervention for women with MBC. If efficacious, FMW-A will help address two national key priorities for management of MBC - enhancing QOL and reducing symptom burden. FMW-A has the potential to address unmet needs and overcome access barriers for this overlooked population, while reducing health system burden. The study was registered prospectively with the ANZCTR on 29/10/2021. Trial ID ACTRN12621001482853p.  https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382714&isReview=true.

Sections du résumé

BACKGROUND BACKGROUND
Women living with metastatic breast cancer (MBC) are at risk of significantly impaired quality of life (QOL), symptom burden, distress and fear of progression, and unmet needs, yet they face barriers to accessing evidence-based psychosocial treatments. Our group therefore developed Finding My Way-Advanced (FMW-A), a web-based self-guided psychosocial program for women with MBC. This study aims to assess its efficacy in improving mental and other QOL domains, distress, fear of progression, unmet needs, and health service utilisation.
METHODS METHODS
The multi-site randomised controlled trial (RCT) will enrol 370 Australian participants. Eligible participants are adult (18 years +) women diagnosed with MBC, with a life expectancy of 6 months or more, with sufficient English-language literacy to provide informed consent. Participants will be identified, screened and referred from one of 10 Australian sites, or via self-referral in response to advertisements. Participants complete four online questionnaires: prior to accessing their program ('baseline'), 6 weeks later ('post-intervention'), then 3 months and 6 months post-intervention. Consenting participants will be randomised to either FMW-A (intervention), or Breast Cancer Network Australia's (BCNA) online/app resource My Journey (minimal intervention attention-control). This is a single-blind study, with randomisation computer-generated and stratified by site. FMW-A is a 6-module program addressing some of the most common issues experienced by women with MBC, with BCNA control resources integrated within the 'resources' section. All modules are immediately accessible, with an additional booster module released 10 weeks later. The primary outcome is mental QOL; statistical criteria for superiority is defined as a 4-point difference between groups at post-treatment. Secondary outcomes include other QOL domains, distress, fear of progression, health service use, intervention adherence, and user satisfaction.
DISCUSSION CONCLUSIONS
This will be the first adequately powered RCT of a self-directed online intervention for women with MBC. If efficacious, FMW-A will help address two national key priorities for management of MBC - enhancing QOL and reducing symptom burden. FMW-A has the potential to address unmet needs and overcome access barriers for this overlooked population, while reducing health system burden.
TRIAL REGISTRATION BACKGROUND
The study was registered prospectively with the ANZCTR on 29/10/2021. Trial ID ACTRN12621001482853p.  https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382714&isReview=true.

Identifiants

pubmed: 36566189
doi: 10.1186/s12885-022-10410-z
pii: 10.1186/s12885-022-10410-z
pmc: PMC9789659
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1353

Subventions

Organisme : Cancer Australia
ID : 2000514

Informations de copyright

© 2022. The Author(s).

Références

J Clin Epidemiol. 2011 Feb;64(2):223-8
pubmed: 21172602
Curr Opin Support Palliat Care. 2018 Sep;12(3):276-292
pubmed: 30074924
Can Fam Physician. 2013 Mar;59(3):e168-74
pubmed: 23486819
Curr Opin Support Palliat Care. 2020 Mar;14(1):40-50
pubmed: 31789944
Support Care Cancer. 2018 Oct;26(10):3489-3496
pubmed: 29693203
Psychooncology. 2020 Jan;29(1):98-106
pubmed: 31483911
Biol Psychol. 2007 Apr;75(1):37-44
pubmed: 17166646
Psychooncology. 2020 Sep;29(9):1430-1435
pubmed: 32691451
J Cancer Surviv. 2021 Jun;15(3):403-409
pubmed: 33723741
Psychooncology. 2020 Feb;29(2):389-397
pubmed: 31703146
Psychooncology. 2005 May;14(5):396-407
pubmed: 15386758
Br J Cancer. 2017 Nov 7;117(10):1486-1494
pubmed: 28926525
Int J Environ Res Public Health. 2020 Oct 28;17(21):
pubmed: 33126692
Psychooncology. 2020 Jan;29(1):76-85
pubmed: 31659822
Holist Nurs Pract. 2017 Jul/Aug;31(4):260-269
pubmed: 28609411
Support Care Cancer. 2017 Jun;25(6):1905-1914
pubmed: 28155018
J Natl Compr Canc Netw. 2010 Apr;8(4):362-6
pubmed: 20410331
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cochrane Database Syst Rev. 2015 May 28;(5):CD008729
pubmed: 26017383
Breast J. 2019 Mar;25(2):290-295
pubmed: 30790383
Cancer. 2015 Feb 15;121(4):614-22
pubmed: 25345778
J Eval Clin Pract. 2009 Aug;15(4):602-6
pubmed: 19522727
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Z Psychosom Med Psychother. 2006;52(3):274-88
pubmed: 17156600
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
Arch Intern Med. 2000 Jul 24;160(14):2101-7
pubmed: 10904452
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
JMIR Res Protoc. 2021 Sep 20;10(9):e31976
pubmed: 34542420
Soc Work Health Care. 2008;47(1):14-29
pubmed: 18956510
Support Care Cancer. 2019 Jul;27(7):2533-2544
pubmed: 30411239
Patient Educ Couns. 2015 Mar;98(3):283-95
pubmed: 25535016
Soc Sci Med. 1991;32(6):705-14
pubmed: 2035047
Support Care Cancer. 2016 Mar;24(3):1043-51
pubmed: 26248651
Support Care Cancer. 2021 Dec;29(12):7669-7678
pubmed: 34142280
Psychooncology. 2012 Jan;21(1):100-7
pubmed: 21105175
Psychooncology. 2018 Jan;27(1):34-42
pubmed: 28432855
Qual Life Res. 1997 Jan;6(1):27-34
pubmed: 9062439
Support Care Cancer. 2018 Jun;26(6):1993-2004
pubmed: 29327085
Curr Opin Support Palliat Care. 2020 Mar;14(1):27-39
pubmed: 31895066

Auteurs

Lisa Beatty (L)

Flinders University, Adelaide, Australia. lisa.beatty@flinders.edu.au.

Emma Kemp (E)

Flinders University, Adelaide, Australia.

Phyllis Butow (P)

University of Sydney, Sydney, Australia.

Afaf Girgis (A)

University of NSW, Sydney, Australia.

Nicholas Hulbert-Williams (N)

Edge Hill University, Ormskirk, UK.

Billingsley Kaambwa (B)

Flinders University, Adelaide, Australia.

Penelope Schofield (P)

Swinburne University, Melbourne, Australia.
Peter MacCallum Cancer Centre, Melbourne, Australia.

Jane Turner (J)

University of Queensland, St Lucia, Australia.

Richard Woodman (R)

Flinders University, Adelaide, Australia.

Frances Boyle (F)

Mater, Sydney, Australia.

Anthony Daly (A)

Cancer Council South Australia, Adelaide, Australia.

Amanda Jones (A)

Southern Adelaide Local Health Network, Bedford Park, Australia.

Belinda Kiely (B)

Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, Australia.

Nicholas Zdenkowski (N)

University of Newcastle, Newcastle, Australia.

Bogda Koczwara (B)

Flinders University, Adelaide, Australia.
Southern Adelaide Local Health Network, Bedford Park, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH